News | September 07, 2021
Indian Pharmaceutical Market grew by 17.7 per cent in August
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
India business contributes to a stellar performance
India business is growing as per projections; whereas US business will bounce back soon.
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
India business grew 11.8% YoY vs mid-single digit industry growth.
The jump in profit is due to the better performance of the API business.
Subscribe To Our Newsletter & Stay Updated
